Stock SGMT SAGIMET BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq
Other stock markets
 03:30:00 28/05/2024 am IST 		5-day change 1st Jan Change
5.17 USD +7.26% Intraday chart for Sagimet Biosciences Inc. +10.00% -4.61%
16/05 Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating MT
15/05 Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sagimet Biosciences Names Thierry Chauche CFO
Sagimet Biosciences Inc. Announces Executive Changes
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Sagimet Biosciences Inc. Announces Management Changes
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Premarket Decliners
Sagimet Biosciences Prices $112.5 Million Common Stock Offering; Shares Fall Pre-Bell
Sagimet Biosciences Launches Public Offering of Series A Common Shares
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care Stocks Higher in Afternoon Trading
Top Midday Gainers
Sagimet Shares Climb After Positive Results From Study of NASH Treatment Denifanstat
Sagimet's shares hit new high as fatty liver disease drug shows promise in study
Sagimet's fatty liver disease drug shows promise in trial
Sagimet Biosciences Announces Positive Topline Results from Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Nash
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMT Stock
  4. News Sagimet Biosciences Inc.
  5. Other languages